New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
07:01 EDTNNVCNanoViricides says President & Chairman Diwan purchased common stock
NanoViricides reports that its President & Chairman Dr. Anil Diwan has purchased its common stock in the open market after the company filed its quarterly report. Dr. Diwan has repaid $83,900 to the company as a result of the “short term profits” accrued from this transaction. “It was very painful to see that our shareholders lost value because of a baseless defamatory article published by an admitted short seller on Seeking Alpha,” said Dr. Diwan, adding, “I have previously purchased stock when a similar precipitous price drop had occurred in February, 2013, despite the fact that the company was progressing well in its goals. Last week, I purchased NNVC stock after the company had already filed the quarterly report in order to signify that we, the executives, have full faith in the company. This was not a transaction for personal profit.”
News For NNVC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
09:14 EDTNNVCNanoViricides provides quarterly report
NanoViricides filed its quarterly report with the SEC estimating that it now has approximately $36.4M of current assets plus restricted cash as of December 31, 2014. The company's operating expenditure during this quarter was approximately $1.9M. Shareholder equity stood at approximately $30.5M for the quarter. The company reported that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as appropriate. The company's anti-Ebola nanoviricide drug candidates have been sent for testing at a prestigious BSL4 facility in the .S. The company has the ability to produce sufficient quantities of a successful drug candidate for potential field use. The company estimates that the cash in hand is sufficient to enable initial human clinical trials of injectable FluCide drug candidate, as well as possibly to advance another drug candidate towards initial human clinical trials.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use